A modified scar model with controlled tension on secondary wound healing in mice

Abstract

Pathological scars might cause a distorted appearance and restricted mobility, and the study of scar pathophysiology has been hindered by the absence of a reliable model. In this study, we introduce a model with a modified device to induce controlled tension on a wound healing by secondary intention to overcome the shortcomings of the model generated by Aarabi et al. We investigated and recommend an induction of 0.1 N/mm² tension on day 7 for 14 days to mimic the characteristics of human scars. A 3.5-fold increase in scar tissue and a 2-fold increase in collagen production were induced by the modified model. Histologically, the modified method increased scar thickness. However, no significant difference was found in cell density between the two groups. This modified procedure significantly increased scar tissue, which could be used for further cellular and biomolecular research. The mechanical force applied to the wound became measurable and controllable. This method is more convenient for researchers to observe in real-time and for providing timely adjustments of the tension used in this modified model.

Keywords

Scar model / Mechanical force / Murine model / Wound healing

References

[1] Sun B, Siprashvili Z, Khavari P. Advances in skin grafting and treatment of cutaneous wounds. Science. 2014; 346: 941-5.

[2] Bombaro K, Engrav L, Carrougher G, Wiechman S, Faucher L, Costa B, et al. What is the prevalence of hypertrophic scarring following burns? Burns. 2003; 29: 299-302.

[3] Wang Y, Beekman J, Hew J, Jackson S, Issler-Fisher A, Parungao R, et al. Burn injury: challenges and advances in burn wound healing, infection, pain and scarring. Adv Drug Deliv Rev. 2018; 123: 3-17.

[4] Amini-Nik S, Yousuf Y, Jeschke M. Scar management in burn injuries using drug delivery and molecular signaling: current treatments and future directions. Adv Drug Deliv Rev. 2018; 123: 135-54.

[5] Richeldi L, du Bois R, Raghu G, Azuma A, Brown K, Costabel U et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2071-82.

[6] King T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2083-92.

[7] Marttala J, Andrews J, Rosenbloom J, Uitto J. Keloids: animal models and pathologic equivalents to study tissue fibrosis. Matrix Biol. 2016; 51: 47-54.

[8] Ahn ST, Mustoe TA. Effects of ischemia on ulcer wound healing: a new model in the rabbit ear. Ann Plast Surg. 1990; 24: 17-23.

[9] Falanga V,Schrayer D,Cha J,Butmarc J,Carson P,Roberts AB, et al. Full-thickness wounding of the mouse tail as a model for delayed wound healing: accelerated wound closure in Smad3 knock-out mice. Wound Repair Regen. 2004; 12: 320-6.

[10] Reid RR, Said HK, Mogford JE, Mustoe TA. The future of wound healing: pursuing surgical models in transgenic and knockout mice. J Am Coll Surg. 2004; 199: 578-85.

[11] Carlson MA, Longaker MT, Thompson JS. Wound splinting regulates granulation tissue survival. J Surg Res. 2003; 110: 304-9.

[12] Davidson JM, Yu F, Opalenik SR. Splinting strategies to overcome confounding wound contraction in experimental animal models. Adv Wound Care (New Rochelle). 2013; 2: 142-8.

[13] Galiano RD, Michaels J, Dobryansky M, Levine JP, Gurtner GC. Quantitative and reproducible murine model of excisional wound healing. Wound Repair Regen. 2004; 12: 485-92.

[14] Aarabi S, Bhatt K, Shi Y, Paterno J, Chang E, Loh S, et al. Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis. FASEB J. 2007; 21: 3250-61.

[15] Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999; 341: 738-46.

[16] Behm B, Babilas P, Landthaler M, Schreml S. Cytokines, chemokines and growth factors in wound healing. J Eur Acad Dermatol Venereol. 2012; 26: 812-20.

[17] Bergmeier V, Etich J, Pitzler L, Frie C, Koch M, Fischer M, et al. Identification of a myofibroblast-specific expression signature in skin wounds. Matrix Biol. 2018; 65: 59-74.

[18] Yang D, Li S, Wu J, Chen Y, Li G, Bi S, et al. Establishment of a hypertrophic scar model by transplanting full-thickness human skin grafts onto the backs of nude mice. Plast Reconstr Surg. 2007; 119: 104-9.

[19] Festing MF, May D, Connors TA, Lovell D, Sparrow S. An athymic nude mutation in the rat. Nature. 1978; 274: 365-6.

[20] Berridge MV, O’Kech N, McNeilage LJ, Heslop BF, Moore R. Rat mutant (NZNU) showing "nude" characteristics. Transplantation. 1979; 27: 410-3.

[21] Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol. 1999; 112: 456-62.

[22] Cameron AM, Adams DH, Greenwood JE, Anderson PJ, Cowin AJ. A novel murine model of hypertrophic scarring using subcutaneous infusion of bleomycin. Plast Reconstr Surg. 2014; 133: 69-78.

[23] Andriessen MP, Niessen FB, Van de Kerkhof PC, Schalkwijk J. Hypertrophic scarring is associated with epidermal abnormalities: an immunohistochemical study. J Pathol. 1998; 186: 192-200.

[24] Ogawa R, Hsu CK. Mechanobiological dysregulation of the epidermis and dermis in skin disorders and in degeneration. J Cell Mol Med. 2013; 17: 817-22.

[25] Jimi S, De Francesco F, Ferraro GA, Riccio M, Hara S. A novel skin splint for accurately mapping dermal Remodeling and epithelialization during wound healing. J Cell Physiol. 2017; 232: 1225-32.

[26] Morris DE, Wu L, Zhao LL, Bolton L, Roth SI, Ladin DA, et al. Acute and chronic animal models for excessive dermal scarring: quantitative studies. Plast Reconstr Surg. 1997; 100: 674-81.